- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04413994
Esclusivo latte materno nei NEOnati prematuri e fattori di rischio di invecchiamento vascolare precoce (NEOVASC) (NEOVASC)
Effetti di una dieta esclusiva a base di latte materno nei neonati prematuri sui fattori di rischio di invecchiamento vascolare precoce (NEOVASC)
Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Early vascular aging has its origins in fetal and neonatal life. This early period of life plays an important role in the development of obesity, high blood pressure, abnormalities in lipid metabolism and non-insulin dependent diabetes. Increased cardiovascular risk in formerly preterm infants constitutes a health problem of steadily growing relevance. Emerging evidence suggests that human milk feeding has substantial benefits to the health of all infants, especially for those born prematurely. Unfortunately, human milk alone does not provide sufficient concentrations of nutrients, especially calcium, phosphorus, protein, and fat needed for these infants to grow satisfactorily. For that purpose, fortifiers are used to help increase the nutritional value of human milk.
The NEOVASC study is a multicentric, prospective, randomized, controlled, open and parallel group clinical trial. A total of 200 extremely preterm infants and 100 term infants are recruited for the test and control group, respectively. Infants in the test group (i.e., premature neonates) are randomized to either:
- An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and a human milk fortifier until 36 weeks of gestation; OR
- Human milk (as long as available) and a human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. Participants within this control group are not enrolled at the time of birth but instead recruited in various kindergartens at the age of five. Therefore, data from birth is taken from the mother-child-booklet, which contains clinical records about the pregnancy, birth and early life of children born in Austria. The total study duration is scheduled for 96 months with a recruitment phase of 36 months. Follow-up visits are planned at one, two and five years of age for the test group.
The purpose of the NEOVASC clinical trial is to characterize early life stressors by assessing the effects of a physiological (i.e., human milk-based) nutrition in extremely preterm infants during the vulnerable preterm period on the risk of metabolic and vascular complications in later life. Outcomes include predictors and intermediate components of cardiovascular disease.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Ursula Kiechl-Kohlendorfer, MD, MSc
- Numero di telefono: +43 512 504 27309
- Email: ursula.kohlendorfer@i-med.ac.at
Backup dei contatti dello studio
- Nome: Wolfgang Mitterer, MD
- Numero di telefono: +43 670 2021490
- Email: wolfgang.mitterer@student.i-med.ac.at
Luoghi di studio
-
-
Tyrol
-
Innsbruck, Tyrol, Austria, A-6020
- Reclutamento
- Medical University of Innsbruck
-
Contatto:
- Ursula Kiechl-Kohlendorfer, MD, MSc
- Numero di telefono: +43 512 504 27309
- Email: ursula.kohlendorfer@i-med.ac.at
-
Contatto:
- Wolfgang Mitterer, MD
- Email: wolfgang.mitterer@student.i-med.ac.at
-
Investigatore principale:
- Christoph Binder, MD
-
Investigatore principale:
- Martin Wald, MD
-
Investigatore principale:
- Burkhard Simma, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Preterm-born group:
Inclusion Criteria:
- Extremely preterm infants with a birth weight of 500-1250g.
- Feeding is NPO or exclusive human milk prior to enrollment.
- Parent(s) willing to sign informed consent.-
Exclusion Criteria:
- Infants with a birth weight <500g or >1250g
- Subjects diagnosed with inborn errors of metabolism such as galactosemia, phenylketonuria
- Subjects who have not been NPO or fed exclusive human milk diet prior to enrollment.
- Presence of major congenital malformation.
- Presence of intestinal perforation or Stage 2 Necrotizing enterocolitis prior to enrollment.
- Parent(s) not willing to sign informed consent.
- Unable to participate for any reason based on the decision of the study investigator (e.g. unlikely to survive the study period).
Term-born group:
Inclusion criteria
- Term-born children with an adequate birth weight
- Parent(s) willing to sign informed consent
Exclusion criteria
- Subjects with acute or chronic illness
- Parent(s) not willing to sign informed consent
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Randomized study product group
receiving study product (human milk fortifier "Humavant") until a gestational age of 36 weeks |
Premature infants are randomized to either:
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. |
|
Comparatore attivo: Randomized control group
receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation |
Premature infants are randomized to either:
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. |
|
Nessun intervento: Term control group
Term-born controls as a reference group for outcome parameters |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Fasting blood glucose
Lasso di tempo: "First day of life" up to "five years of life"
|
Primary outcome is the difference in fasting blood glucose at five years of age |
"First day of life" up to "five years of life"
|
|
Blood pressure
Lasso di tempo: "First day of life" up to "five years"
|
Primary outcome is the difference in blood pressure at five years of age |
"First day of life" up to "five years"
|
|
Distensibility of aorta
Lasso di tempo: "First day of life" up to "five years"
|
Primary outcome is the difference in the distensibility of the descending aorta using validated echocardiographic protocols at five years of age |
"First day of life" up to "five years"
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Fasting blood glucose
Lasso di tempo: "First day of life" up to "24 months"
|
Secondary outcome is fasting glucose at a corrected age of one and two years. |
"First day of life" up to "24 months"
|
|
Blood pressure
Lasso di tempo: "First day of life" up to "24 months"
|
Secondary outcome is blood pressure at a corrected age of one and two years. |
"First day of life" up to "24 months"
|
|
BMI
Lasso di tempo: "First day of life" up to "five years"
|
Secondary outcome is BMI at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2 |
"First day of life" up to "five years"
|
|
Insulin sensitivity
Lasso di tempo: "First day of life" up to "five years"
|
Secondary outcome is insulin sensitivity at five years of age |
"First day of life" up to "five years"
|
|
Lipid profile
Lasso di tempo: "First day of life" up to "five years"
|
Secondary outcome is lipid profile at five years of age |
"First day of life" up to "five years"
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Fasting blood glucose
Lasso di tempo: "five years of age"
|
Difference in fasting blood glucose between preterm- and term-born children at five years of age |
"five years of age"
|
|
Blood pressure
Lasso di tempo: "five years of age"
|
Difference in blood pressure between preterm- and term-born children at five years of age |
"five years of age"
|
|
Distensibility of the descending aorta
Lasso di tempo: "five years of age"
|
Difference in the distensibility of the descending aorta between preterm- and term-born children using validated echocardiographic protocols at five years of age Results will be compared to results of term-born children |
"five years of age"
|
|
BMI
Lasso di tempo: "five years of age"
|
Difference in BMI between preterm- and term-born children at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2 |
"five years of age"
|
|
Insulin sensitivity
Lasso di tempo: "five years of age"
|
Difference in insulin sensitivity between preterm- and term-born children at five years of age |
"five years of age"
|
|
Lipid profile
Lasso di tempo: "five years of age"
|
Difference in lipid profile between preterm- and term-born children at five years of age |
"five years of age"
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Ursula Kiechl-Kohlendorfer, MD, MSc, Medical University Innsbruck
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- NEOVASC
- 868624 (Altro numero di sovvenzione/finanziamento: Austrian Research Promotion Agency)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .